United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD

UNITED THERAPEUTICS Corp

DSMC recommended termination after routine safety and efficacy analysis.
Study evaluated Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension with COPD.
Company will review available data and share results with the scientific community.
Tyvaso is already approved for PAH and PH-ILD; termination affects a potential label expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.